Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib

被引：0
|
作者：
Hua Cheng
She-Juan An
Song Dong
Yi-Fang Zhang
Xu-Chao Zhang
Zhi-Hong Chen
Yi-Long Jian-Su
机构：
[1] Guangdong Lung Cancer Institute; Medical Research Center of Guangdong General Hospital & Guangdong Academy of Medical Sciences,
[2] Thoracic oncology,undefined
[3] the fifth affiliated hospital of Sun Yat-Sen university,undefined
来源：
Journal of Hematology & Oncology | / 4卷
关键词：
Paclitaxel; Gefitinib; Erlotinib; H1650 Cell; Combination Index;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs
    Tone, Mari
    Iwahori, Kota
    Shiroyama, Takayuki
    Futami, Shinji
    Naito, Yujiro
    Fukushima, Kiyoharu
    Miyake, Kotaro
    Koyama, Shohei
    Hirata, Haruhiko
    Nagatomo, Izumi
    Wada, Hisashi
    Takeda, Yoshito
    Kumanogoh, Atsushi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [22] Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines
    Zoli, W
    Ricotti, L
    Barzanti, F
    Dal Susino, M
    Frassineti, GL
    Milandri, C
    Giunchi, DC
    Amadori, D
    INTERNATIONAL JOURNAL OF CANCER, 1999, 80 (03) : 413 - 416
  • [23] Differential effects of gefitinib and cetuximab on EGFR mutant non-small cell lung cancers (NSCLC) cell lines
    Mukohara, T
    Engelman, J
    Lindeman, N
    Pearlberg, J
    Cantley, L
    Johnson, B
    Jänne, P
    LUNG CANCER, 2005, 49 : S7 - S7
  • [24] In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines
    Tanaka, R
    Ariyama, H
    Qin, BL
    Takii, Y
    Baba, E
    Mitsugi, K
    Harada, M
    Nakano, S
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (06) : 595 - 601
  • [25] In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines
    Risa Tanaka
    Hiroshi Ariyama
    Baoli Qin
    Yasushi Takii
    Eishi Baba
    Kenji Mitsugi
    Mine Harada
    Shuji Nakano
    Cancer Chemotherapy and Pharmacology, 2005, 55 : 595 - 601
  • [26] Erlotinib response EGFR-mutant gefitinib-resistant non-small-cell lung cancer
    Chang, John Wen-Cheng
    Chou, Chun-Liang
    Huang, Shiu-Feng
    Wang, Hung-Ming
    Hsieh, Jia-Juan
    Hsu, Todd
    Cheung, Yun-Chung
    LUNG CANCER, 2007, 58 (03) : 414 - 417
  • [27] Transcriptomic Heterogeneity of EGFR-Mutant Non-Small Cell Lung Cancer Evolution Toward Small-Cell Lung Cancer
    Oh, Songji
    Koh, Jaemoon
    Kim, Tae Min
    Kim, Soyeon
    Youk, Jeonghwan
    Kim, Miso
    Keam, Bhumsuk
    Jeon, Yoon Kyung
    Ku, Ja-Lok
    Kim, Dong-Wan
    Chung, Doo Hyun
    Heo, Dae Seog
    CLINICAL CANCER RESEARCH, 2024, 30 (20) : 4729 - 4742
  • [28] Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro
    Akutsu, M
    Kano, Y
    Tsunoda, S
    Suzuki, K
    Yazawa, Y
    Miura, Y
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (13-14) : 2341 - 2346
  • [29] Radiomic Signature to Predict Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer
    Minatta, J. N.
    Deza, D.
    Aineseder, M.
    Nunez, M. Mestas
    Mosquera, C.
    Lupinacci, L.
    Benitez, S.
    Seehaus, A.
    Luna, D.
    Beresnak, A.
    Diaz, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1166 - S1166
  • [30] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
    Ana Ortega-Franco
    Shereen Rafee
    Oncology and Therapy, 2022, 10 : 13 - 22
12345